Cargando…

Utility of interval kidney biopsy in ANCA-associated vasculitis

OBJECTIVES: ANCA-associated vasculitis (AAV) is a rare autoimmune disorder that commonly involves the kidney. Early identification of kidney involvement, assessing treatment-response and predicting outcome are important clinical challenges. Here, we assessed the potential utility of interval kidney...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Gavin B, Farrah, Tariq E, Chapman, Fiona A, Pugh, Dan, Bellamy, Christopher O C, Lahiri, Rashmi, Miller-Hodges, Eve, Kluth, David C, Hunter, Robert W, Dhaun, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071515/
https://www.ncbi.nlm.nih.gov/pubmed/34505902
http://dx.doi.org/10.1093/rheumatology/keab695
_version_ 1784700857857605632
author Chapman, Gavin B
Farrah, Tariq E
Chapman, Fiona A
Pugh, Dan
Bellamy, Christopher O C
Lahiri, Rashmi
Miller-Hodges, Eve
Kluth, David C
Hunter, Robert W
Dhaun, Neeraj
author_facet Chapman, Gavin B
Farrah, Tariq E
Chapman, Fiona A
Pugh, Dan
Bellamy, Christopher O C
Lahiri, Rashmi
Miller-Hodges, Eve
Kluth, David C
Hunter, Robert W
Dhaun, Neeraj
author_sort Chapman, Gavin B
collection PubMed
description OBJECTIVES: ANCA-associated vasculitis (AAV) is a rare autoimmune disorder that commonly involves the kidney. Early identification of kidney involvement, assessing treatment-response and predicting outcome are important clinical challenges. Here, we assessed the potential utility of interval kidney biopsy in AAV. METHODS: In a tertiary referral centre with a dedicated vasculitis service, we identified patients with AAV who had undergone interval kidney biopsy, defined as a repeat kidney biopsy (following an initial biopsy showing active AAV) undertaken to determine the histological response in the kidney following induction immunosuppression. We analysed biochemical, histological and outcome data, including times to kidney failure and death for all patients. RESULTS: We identified 57 patients with AAV who underwent at least one interval kidney biopsy (59 interval biopsies in total; median time to interval biopsy ∼130 days). Of the 59 interval biopsies performed, 24 (41%) patients had clinically suspected active disease at time of biopsy which was confirmed histologically in only 42% of cases; 35 (59%) patients were in clinical disease-remission, and this was correct in 97% of cases. The clinician’s impression was incorrect in one in four patients. Hematuria at interval biopsy did not correlate with histological activity. Interval biopsy showed fewer acute lesions and more chronic damage compared with initial biopsy and led to immunosuppressive treatment-change in 75% (44/59) of patients. Clinical risk prediction tools tended to operate better using interval biopsy data. CONCLUSION: Interval kidney biopsy is useful for determining treatment-response and subsequent disease management in AAV. It may provide better prognostic information than initial kidney biopsy and should be considered for inclusion into future clinical trials and treatment protocols for patients with AAV.
format Online
Article
Text
id pubmed-9071515
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90715152022-05-06 Utility of interval kidney biopsy in ANCA-associated vasculitis Chapman, Gavin B Farrah, Tariq E Chapman, Fiona A Pugh, Dan Bellamy, Christopher O C Lahiri, Rashmi Miller-Hodges, Eve Kluth, David C Hunter, Robert W Dhaun, Neeraj Rheumatology (Oxford) Clinical Science OBJECTIVES: ANCA-associated vasculitis (AAV) is a rare autoimmune disorder that commonly involves the kidney. Early identification of kidney involvement, assessing treatment-response and predicting outcome are important clinical challenges. Here, we assessed the potential utility of interval kidney biopsy in AAV. METHODS: In a tertiary referral centre with a dedicated vasculitis service, we identified patients with AAV who had undergone interval kidney biopsy, defined as a repeat kidney biopsy (following an initial biopsy showing active AAV) undertaken to determine the histological response in the kidney following induction immunosuppression. We analysed biochemical, histological and outcome data, including times to kidney failure and death for all patients. RESULTS: We identified 57 patients with AAV who underwent at least one interval kidney biopsy (59 interval biopsies in total; median time to interval biopsy ∼130 days). Of the 59 interval biopsies performed, 24 (41%) patients had clinically suspected active disease at time of biopsy which was confirmed histologically in only 42% of cases; 35 (59%) patients were in clinical disease-remission, and this was correct in 97% of cases. The clinician’s impression was incorrect in one in four patients. Hematuria at interval biopsy did not correlate with histological activity. Interval biopsy showed fewer acute lesions and more chronic damage compared with initial biopsy and led to immunosuppressive treatment-change in 75% (44/59) of patients. Clinical risk prediction tools tended to operate better using interval biopsy data. CONCLUSION: Interval kidney biopsy is useful for determining treatment-response and subsequent disease management in AAV. It may provide better prognostic information than initial kidney biopsy and should be considered for inclusion into future clinical trials and treatment protocols for patients with AAV. Oxford University Press 2021-09-10 /pmc/articles/PMC9071515/ /pubmed/34505902 http://dx.doi.org/10.1093/rheumatology/keab695 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Chapman, Gavin B
Farrah, Tariq E
Chapman, Fiona A
Pugh, Dan
Bellamy, Christopher O C
Lahiri, Rashmi
Miller-Hodges, Eve
Kluth, David C
Hunter, Robert W
Dhaun, Neeraj
Utility of interval kidney biopsy in ANCA-associated vasculitis
title Utility of interval kidney biopsy in ANCA-associated vasculitis
title_full Utility of interval kidney biopsy in ANCA-associated vasculitis
title_fullStr Utility of interval kidney biopsy in ANCA-associated vasculitis
title_full_unstemmed Utility of interval kidney biopsy in ANCA-associated vasculitis
title_short Utility of interval kidney biopsy in ANCA-associated vasculitis
title_sort utility of interval kidney biopsy in anca-associated vasculitis
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071515/
https://www.ncbi.nlm.nih.gov/pubmed/34505902
http://dx.doi.org/10.1093/rheumatology/keab695
work_keys_str_mv AT chapmangavinb utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT farrahtariqe utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT chapmanfionaa utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT pughdan utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT bellamychristopheroc utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT lahirirashmi utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT millerhodgeseve utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT kluthdavidc utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT hunterrobertw utilityofintervalkidneybiopsyinancaassociatedvasculitis
AT dhaunneeraj utilityofintervalkidneybiopsyinancaassociatedvasculitis